Highlight selection of radiochemistry and radiopharmacy developments by editorial board

BackgroundThe Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in the field of radiopharmaceutical development.Main BodyThis selection of highlights provides commentary on 21different topics selected by each coauthoring Editorial Board member addressinga variety of aspects ranging from novel radiochemistry to first-in-humanapplication of novel radiopharmaceuticals.ConclusionTrends in radiochemistry and radiopharmacy arehighlighted. Hot topics cover the entire scope of EJNMMI Radiopharmacy andChemistry, demonstrating the progress in the research field, and include newPET-labelling methods for C-11 and F-18, the importance ofchoosing the proper chelator for a given radioactive metal ion, implications oftotal body PET on use of radiopharmaceuticals, legislation issues andradionuclide therapy including the emerging role of Tb-161.

Automated summary

This article is a biannual highlight commentary released by the Editorial Board of EJNMMI Radiopharmacy and Chemistry to update readers on trends in radiopharmaceutical development. The authors provide commentary on 21 different topics, including novel radiochemistry and the first-in-human application of novel radiopharmaceuticals. The trends in radiochemistry and radiopharmacy are highlighted, covering various aspects such as new PET-labelling methods, the importance of choosing the proper chelator for a given radioactive metal ion, implications of total body PET on the use of radiopharmaceuticals, legislation issues, and the emerging role of Tb-161 in radionuclide therapy.